<DOC>
	<DOCNO>NCT02966340</DOCNO>
	<brief_summary>Double-blind , placebo-controlled , cross-over design study examine effect norepinephrine alpha1 receptor antagonist ( prazosin ) stress reactivity laboratory stressor task .</brief_summary>
	<brief_title>Repurposing alpha1 Noradrenergic Antagonists Alcoholism Treatment</brief_title>
	<detailed_description>OBJECTIVES The first objective current study examine norepinephrine alpha1 ( NE-alpha1 ) receptor involvement reactivity unpredictable stressor human , use NPU stress task conjunction alpha1-blocker , prazosin . The second objective study provide preliminary evidence prazosin effective reduce stress-reactivity alcoholic early abstinence . PARTICIPANTS Sixty-four healthy adult participant sixty-four participant Alcohol Use Disorder early abstinence . STUDY OVERVIEW Sixty-four healthy adult participant ( 32 male &amp; 32 female ) recruit participate double-blind , placebo-controlled , cross-over design study examine effect NE-alpha1 antagonist ( prazosin ) defensive ( physiological self-report affect ) response stressor use well-validated animal-human translational stressor task . Participants complete two overnight study visit 2 mg prazosin placebo administer separate visit separate approximately 7 day . Drug order randomly assign counterbalance across participant ( double-blind ; study visit 1-2 ) . On two study visit , participant complete No Shock , Predictable Shock , Unpredictable Shock ( NPU ) task 90 minute drug administration . The NPU task design examine stress reactivity predictable unpredictable stressor ( i.e. , electric shock ) . These two visit provide within-subject evaluation effect acute antagonism alpha1-NE receptor ( via prazosin ) investigate role NE mechanism unpredictable ( vs. predictable ) stressor response . After full healthy adult/control sample complete study , investigator conduct preliminary data analysis evaluate first study hypothesis . These analysis use evaluate sensitivity NPU task NE-alpha1 mechanisms potential utility early surrogate endpoint stress-related relapse mechanism alcoholism . The investigator recruit sample sixty-four alcoholic participant complete study first hypothesis initially support healthy control . These participant meet DSM5 criterion Alcohol Use Disorder ( least moderate severity ) early abstinence ( 1-8 week ) . All study procedure identical sample . OUTCOME MEASURES The primary outcome startle potentiation NPU task secondary outcome self-reported retrospective fear/anxiety NPU task . HYPOTHESES 1 . Prazosin ( 2mg vs. placebo ) reduce stress reactivity unpredictable ( vs. predictable ) stressor measure via startle potentiation self-report . 2 . Abstinent alcoholic ( vs. control ) display elevate stress reactivity unpredictable ( vs. predictable ) stressor measure via startle potentiation self-report . 3 . The predicted effect prazosin reduce stress reactivity unpredictable ( vs. predictable ) stressor ( Hypothesis 1 ) measure via startle potentiation self-report moderate alcoholism , effect prazosin large abstinent alcoholic control participant .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<criteria>INCLUSION CRITERIA : All Participants Can read write English . Ages 1850 year . INCLUSION CRITERIA : Control Participants No current lifetime history Substance Use Disorder ( except tobacco ) . INCLUSION CRITERIA : Alcoholic Participants Current Alcohol Use Disorder 18 week completely free alcohol consumption . Exclusion criterion divide three broad category Medical , Psychiatric/Behavioral , Medications/Therapies . EXCLUSION CRITERIA : Medical Colorblind Blood alcohol concentration ( BAC ) &gt; 0.00 Systolic BP &lt; 100 five minute seat . Systolic BP drop &gt; 20mmHg two minute stand . Systolic BP drop &gt; 10mgHG AND report dizziness , lightheadedness , unsteadiness problem ( e.g , nausea , blurry vision ) two minute stand . Heart rate &gt; 100 beats/ minute two minute seat . Heart rate &lt; 60 beats/ minute two minute seat . Scheduled cataract surgery prior study completion . Past current coronary artery disease , cerebrovascular accident , congestive heart failure . Current renal insufficiency , liver insufficiency , pancreatitis , immunosuppressive therapy , cancer systemic effect therapy . Benign positional vertigo , Meniere 's disease narcolepsy Current diabetes polyneuropathy Previous allergic adverse reaction prazosin alpha1 norepinephrine antagonist . Other selfreported acute unstable illness , opinion study team , would preclude safe reliable study participation . EXCLUSION CRITERIA : Female Participants Only Nonnegative urine pregnancy test . Women childbearing potential ( see definition ) must agree use one follow form birth control study completion . Acceptable birth control define follow method contraception : abstinence ; hormonal contraceptive ( e.g . combine oral contraceptive , patch , vaginal ring , injectables , implant ) ; intrauterine device ( IUD ) intrauterine system ( IUS ) ; vasectomy partner tubal ligation ; `` single '' barrier method contraception ( e.g . male condom , female condom , cervical cap , diaphragm , contraceptive sponge ) use spermicide ; `` double barrier '' method contraception ( e.g . male condom diaphragm , male condom cervical cap ) . Breastfeeding NOTE : Women childbearing potential female experience menarche meet criterion woman childbearing potential . Women childbearing potential female permanently sterile ( e.g. , hysterectomy , bilateral oophorectomy ) postmenopausal . Postmenopausal define 12 consecutive month menses without alternative medical cause . EXCLUSION CRITERIA : Psychological/Behavioral Exclusion Selfreported lifetime diagnosis schizophrenia , schizoaffective disorder , psychotic disorder NOS , bipolar disorder , borderline personality disorder , neurocognitive disorder . EXCLUSION CRITERIA : Medications/Therapies Currently prescribe use within 72 hour : prazosin alpha1NE antagonist ( e.g. , doxazosin , terazosin ) . Previous adequate trial prazosin alcohol use disorder PTSD . Currently prescribe use within 72 hour : Stimulants ( e.g. , damphetamine , methylphenidate ) alternative medication stimulant property ( e.g. , ephedra , pseudoephedrine ) . Currently prescribe use within 72 hour : Sildenafil ( Viagra ) , tadalafil ( Cialis ) , vardenafil ( Levitra ) . Currently prescribe use within 72 hour : betablockers ( e.g. , propranolol ) , alpha2 agonist ( e.g. , clonidine , guanfacine ) , SNRI antidepressant ( e.g. , venlafaxine , duloxetine ) . Currently use daily use within 72 hour : alpha1 agonist ( e.g. , midodrine , metaraminol , oxymetazoline , phenylephrine ) . Currently use daily use within 72 hour : Benzodiazepines ( e.g. , diazepam , chlordiazepoxide , lorazepam , clonazepam , alprazolam ) , zolpidem ( Ambien ) , zaleplon ( Sonata ) , zopiclone ( Imovane ) , eszopiclone ( Lunesta ) , doxepin ( Silenor ) . Currently prescribe use daily use within 72 hour : Trazodone ( male )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Alcoholism</keyword>
	<keyword>Prazosin</keyword>
	<keyword>Startle Potentiation</keyword>
	<keyword>Norepinephrine</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Fear</keyword>
	<keyword>Stress</keyword>
</DOC>